Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA

Journal of Clinical Microbiology

Volumn 43, Issue 2, 2005, Pages 596-603

  Konnick, Eric Q ^a,c   Erali, Maria ^a   Ashwood, Edward R ^a,b   Hillyard, David R ^a,b  

^a ARUP LABORATORIES   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ACCURACY; ANALYTICAL EQUIPMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; EVALUATION; HEPATITIS B VIRUS; HUMAN; LINEAR SYSTEM; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS TITRATION;

DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; ULTRACENTRIFUGATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 13844267384     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.2.596-603.2005     Document Type: Article

References (56)

1. Aspinall, S., A. D. Steele, I. Peenze, and M. J. Mphahlele. 1995. Detection and quantitation of hepatitis B virus DNA: comparison of two commercial hybridization assays with polymerase chain reaction. J. Viral Hepatitis 2:107-1411.
2. Brechtbuehl, K., S. A. Whalley, G. M. Dusheiko, and N. A. Saunders. 2001. A rapid real-time quantitative polymerase chain reaction for hepatitis B virus. J. Virol. Methods 93:105-113.
3. Butterworth, L. A., S. L. Prior, P. J. Buda, J. L. Faoagali, and W. G. Cooksley. 1996. Comparison of four methods for quantitative measurement of hepatitis B viral DNA. J. Hepatol. 24:686-691.
4. Chu, C. J., M. Hussain, and A. S. Lok. 2002. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 36:1408-1415.
5. de Man, R. A., P. Marcellin, F. Habal, P. Desmond, T. Wright, T. Rose, R. Jurewicz, and C. Young. 2000. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 32:413-417.
6. DiDomenico, N., H. Link, R. Knobel, T. Caratsch, W. Weschler, Z. G. Loewy, and M. Rosenstraus. 1996. COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin. Chem. 42:1915-1923.
7. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
8. Di Marco, V., O. Lo Iacono, C. Camma, A. Vaccaro, M. Giunta, G. Martorana, P. Fuschi, P. L. Almasio, and A. Craxi. 1999. The long-term course of chronic hepatitis B. Hepatology 30:257-264.
9. Evans, A. A., A. P. O'Connell, J. C. Pugh, W. S. Mason, F. M. Shen, G. C. Chen, W. Y. Lin, A. Dia, S. M'Boup, B. Drame, and W. T. London. 1998. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prevent. 7:559-565.
10. Fei, G. Z., S. P. Sylvan, G. B. Yao, and U. B. Hellstrom. 1999. Quantitative monitoring of serum hepatitis B virus DNA and blood lymphocyte subsets during combined prednisolone and interferon-alpha therapy in patients with chronic hepatitis B. J. Viral Hepatitis 6:219-227.
11. Heermann, K. H., W. H. Gerlich, M. Chudy, S. Schaefer, R. Thomssen, and the Eurohep Pathobiology Group. 1999. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. J. Clin. Microbiol. 37:68-73.
12. Hennig, H., I. Puchta, J. Luhm, P. Schlenke, S. Goerg, and H. Kirchner. 2002. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 100:2637-2641.
13. Hilleman, M. R. 2001. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19:1837-1848.
14. Ho, S. K., T. M. Chan, I. K. Cheng, and K. N. Lai. 1999. Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. J. Clin. Microbiol. 37:2461-2465.
15. Ho, S. K., W. C. Yam, E. T. Leung, L. P. Wong, J. K. Leung, K. N. Lai, and T. M. Chan. 2003. Rapid quantification of hepatitis B virus DNA by real-time PCR using fluorescent hybridization probes. J. Med. Microbiol. 52:397-402.
16. Hwang, S.-J., R.-H. Lu, M. L. Wood, Y.-J. Wang, F.-Y. Chang, and S.-D. Lee. 1999. Comparison of the nucleic acid-based crosslinking hybridization assay and the branched DNA signal amplification assay in the quantitative measurement of serum hepatitis B virus DNA. J. Clin. Lab. Anal. 13:296-300.
17. Janssen, H. L., G. Gerken, V. Carren̄o, P. Marcellin, N. V. Naoumov, A. Craxi, H. Ring-Larsen, G. Kitis, J. van Hattum, R. A. de Vries, P. P. Michielsen, F. J. ten Kate, W. C. Hop, R. A. Heijtink, P. Honkoop, S. W. Schalm, et al. 1999. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. Hepatology 30:238-243.
18. Kao, J. H., M. Wood, P. J. Chen, M. Y. Lai, and D. S. Chen. 1999. Comparison of two methods for quantification of hepatitis B viral DNA. J. Gastroenterol. Hepatol. 14:423-426.
19. Kessler, H. H., K. Pierer, E. Dragon, H. Lackner, B. Santner, D. Stunzner, E. Stelzl, B. Waitzl, and E. Marth. 1998. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin. Diagn. Virol. 9:37-43.
20. Kessler, H. H., S. Preininger, E. Stelzl, E. Daghofer, B. I. Santner, E. Marth, H. Lackner, and R. E. Stauber. 2000. Identification of different states of hepatitis B virus infection with a quantitative PCR assay. Clin. Diagn. Lab. Immunol. 7:298-300.
21. Kessler, H. H., E. Stelzl, E. Daghofer, B. I. Santner, E. Marth, H. Lackner, and R. E. Stauber. 2000. Semiautomated quantification of hepatitis B virus DNA in a routine diagnostic laboratory. Clin. Diagn. Lab. Immunol. 7:853-855.
22. Krajden, M., J. Minor, L. Cork, and L. Comanor. 1998. Multi-measurement method comparison of three commercial hepatitis B virus DNA quantification assays. J. Viral Hepatitis 5:415-422.
23. Kuhns, M. C., A. L. McNamara, R. P. Perrillo, C. M. Cabal, and C. R. Campbel. 1989. Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J. Med. Virol. 27:274-281.
24. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, D. F. Gray, et al. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
25. Lai, C. L., M. Rosmawati, J. Lao, H. Van Vlierberghe, F. H. Anderson, N. Thomas, and D. Dehertogh. 2002. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123:1831-1838.
26. Lau, G. K., M. Tsiang, J. Hou, S. Yuen, W. F. Carman, L. Zhang, C. S. Gibbs, and S. Lam. 2000. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 32:394-399.
27. Leung, N. W. Y., C.-L. Lai, T.-T. Chang, R. Guan, C.-M. Lee, K.-Y. Ng, S.-G. Lim, P.-C. Wu, J. C. Dent, S. Edmundson, L. D. Condreay, and R.-N. Chien. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
28. Lewin, S. R., R. M. Ribeiro, T. Walters, G. K. Lau, S. Bowden, S. Locarnini, and A. S. Perelson. 2001. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 34:1012-1020.
29. Liu, C. J., P. J. Chen, M. Y. Lai, J. H. Kao, and D. S. Chen. 2001. Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences. Hepatology 34:583-589.
30. Loeb, K., K. Jerome, J. Goddard, M. Huang, A. Cent, and L. Corey. 2000. High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. Hepatology 32:626-629.
31. Lok, A. S., E. J. Heathcote, and J. H. Hoofnagle. 2001. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 120:1828-1853.
32. Lok, A. S., and B. J. McMahon. 2001. Chronic hepatitis B. Hepatology 34:1225-1241.
33. Mahoney, F. J. 1999. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin. Microbiol. Rev. 12:351-366.
34. Makris, A., L. Zignego, and S. J. Hadziyannis. 1991. Measurement of hepatitis B viral DNA in serum by solution hybridization and comparison with the dot-blot hybridization technique. Hepatogastroenterology 38:53-55.
35. Marin, I. J., M. Poljak, K. Seme, J. Meglic-Volkar, M. Maticic, G. Lesnicar, and V. Brinovec. 2001. Comparative evaluation of semiautomated COBAS AMPLICOR hepatitis B virus (HBV) MONITOR test and manual microwell plate-based AMPLICOR HBV MONITOR test. J. Clin. Microbiol. 39:758-761.
36. Michalak, T. I., C. Pasquinelli, S. Guilhot, and F. V. Chisari. 1994. Hepatitis B virus persistence after recovery from acute viral hepatitis. J. Clin. Investig. 93:230-239.
37. Mommeja-Marin, H., E. Mondou, M. R. Blum, and F. Rousseau. 2003. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37:1309-1319.
38. Mutimer, D., D. Dowling, P. Cane, D. Ratcliffe, H. Tang, K. O'Donnell, J. Shaw, E. Elias, and D. Pillay. 2000. Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection. Antivir. Ther. 5:273-277.
39. Nagata, I., G. Colucci, G. V. Gregorio, P. Cheeseman, R. Williams, G. Mieli-Vergani, and D. Vergani. 1999. The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. J. Hepatol. 30:965-969.
40. Niesters, H. G., M. Krajden, L. Cork, M. de Medina, M. Hill, E. Fries, and A. D. Osterhaus. 2000. A multicenter study evaluation of the Digene Hybrid Capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards. J. Clin. Microbiol. 38:2150-2155.
41. Noborg, U., A. Gusdal, P. Horal, and M. Lindh. 2000. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand. J. Infect. Dis. 32:249-252.
42. Noborg, U., A. Gusdal, E. K. Pisa, A. Hedrum, and M. Lindh. 1999. Automated quantitative analysis of hepatitis B virus DNA by using the Cobas Amplicor HBV monitor test. J. Clin. Microbiol. 37:2793-2797.
43. Nolte, F. S. 1998. Branched DNA signal amplification for direct quantitation of nucleic acid sequences in clinical specimens. Adv. Clin. Chem. 33:201-235.
44. Paraskevis, D., C. Haida, N. Tassopoulos, M. Raptopoulou, D. Tsantoulas, H. Papachristou, V. Sypsa, and A. Hatzakis. 2002. Development and assessment of a novel real-time PCR assay for quantitation of HBV DNA. J. Virol. Methods 103:201-212.
45. Pas, S. D., E. Fries, R. A. De Man, A. D. Osterhaus, and H. G. Niesters. 2000. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J. Clin. Microbiol. 38:2897-2901.
46. Poljak, M., I. J. Marin, K. Seme, V. Brinovec, M. Maticic, J. Meglic-Volkar, G. Lesnicar, and A. Vince. 2001. Second-generation hybrid capture test and Amplicor monitor test generate highly correlated hepatitis B virus DNA levels. J. Virol. Methods 97:165-169.
47. Roche, B., C. Feray, M. Gigou, A. M. Roque-Afonso, J. L. Arulnaden, V. Delvart, E. Dussaix, C. Guettier, H. Bismuth, and D. Samuel. 2003. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology 38:86-95.
48. Roth, W. K., S. Buhr, C. Drosten, and E. Seifried. 2000. NAT and viral safety in blood transfusion. Vox Sang 78(Suppl. 2):257-259.
49. Saldanha, J., W. Gerlich, N. Lelie, P. Dawson, K. Heermann, and A. Heath. 2001. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 80:63-71.
50. Tsiang, M., J. F. Rooney, J. J. Toole, and C. S. Gibbs. 1999. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 29:1863-1869.
51. Weusten, J. J., H. A. van Drimmelen, and P. N. Lelie. 2002. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 42:537-548.
52. Wolters, L. M., B. E. Hansen, H. G. Niesters, S. Zeuzem, S. W. Schalm, and R. A. de Man. 2002. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 22:121-126.
53. Yotsuyanagi, H., K. Yasuda, S. Iino, K. Moriya, Y. Shintani, H. Fujie, T. Tsutsumi, S. Kimura, and K. Koike. 1998. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 27:1377-1382.
54. Yuen, M. F., E. Sablon, C. K. Hui, H. J. Yuan, H. Decraemer, and C. L. Lai. 2001. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34:785-791.
55. Zanella, I., A. Rossini, D. Domenighini, A. Albertini, and E. Cariani. 2002. Quantitative analysis of hepatitis B virus DNA by real-lime amplification. Eur. J. Clin. Microbiol. Infect. Dis. 21:22-26.
56. Zollner, B., P. Schafer, H. H. Feucht, M. Schroter, J. Petersen, and R. Laufs. 2001. Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J. Med. Virol. 65:659-663.